University Medical Center Göttingen Trials

University Medical Center Göttingen	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Hasenkamp, Justin

TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL

Recruiting

870

Europe

R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)

Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum

Mantle Cell Lymphoma

05/21

05/26

AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting

482

Europe

Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)

Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH

Multiple Myeloma

03/28

03/33

DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting

168

Europe, RoW

MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab

Miltenyi Biomedicine GmbH, ICON plc

Diffuse Large B-cell Lymphoma

12/24

07/29

NCT03853616 / 2017-002848-32: MB-CART19.1 R/r CD19+ B-cell Malignancies (BCM)

Recruiting

1/2

Europe

MB-CART19.1, CD19-targeting CAR T cells, Anti-CD19 CAR T cells

Miltenyi Biomedicine GmbH

Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent, Chronic Lymphocytic Leukemia Refractory

12/24

Wiltfang, Jens

ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated

1027

Europe, Canada, Japan, US, RoW

Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo

Biogen, Biogen Idec Research Limited

Alzheimer's Disease

08/24

CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting

416

Europe, Canada, Japan, US, RoW

BIIB080, ISIS 814907, BIIB080-matching placebo

Biogen

Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

05/26

01/29

NCT06149013: Efficacy of MindAhead's Digital Behavioral Activation Therapy in Adults with MCI or Mild Dementia

Completed

N/A

Europe

MindAhead Active, MindAhead's Behavioral Activation Therapy, Treatment-as-usual, TAU

MindAhead UG, University Medical Center Göttingen

Mild Cognitive Impairment, Mild Dementia

10/24

Arnim, Christine von

NCT06149013: Efficacy of MindAhead's Digital Behavioral Activation Therapy in Adults with MCI or Mild Dementia

Completed

N/A

Europe

MindAhead Active, MindAhead's Behavioral Activation Therapy, Treatment-as-usual, TAU

MindAhead UG, University Medical Center Göttingen

Mild Cognitive Impairment, Mild Dementia

10/24

Quintel, Michael

ARISS, NCT03869385: Albumin Replacement Therapy in Septic Shock

Terminated

440

Europe

Albutein® 200 g/L or Plasbumin® 20, Human Albumin 20%

Jena University Hospital, German Research Foundation, Instituto Grifols, S.A., University Hospital Goettingen, SepNet - Critical Care Trials Group, Center for Sepsis Control and Care, Germany

Septic Shock

07/22

06/23

NCT04249414: Post-hoc Analysis of Regional Pulmonary Perfusion and Hemodynamic Parameters Measured by Electrical Impedance Tomography

Suspended

N/A

Europe

PulmoVista 500

Drägerwerk AG & Co. KGaA, University of Göttingen, Prof. Dr. med. Imhoff

Mechanical Ventilation, Ventilation Perfusion Mismatch

06/24

12/24

Danner, Bernd

PACES, NCT04045665 / 2021-005022-18: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting

3200

Europe, Canada, US

Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy

Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University Medical Center

Atrial Fibrillation, Stroke, Bleeding

08/26

NCT04124120: Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

Recruiting

N/A

2000

Europe, Canada, Japan, US, RoW

Single arterial graft, Multiple arterial grafting

Weill Medical College of Cornell University, New York Presbyterian Hospital, Sunnybrook Health Sciences Centre, Cedars-Sinai Medical Center, Columbia University, Duke University

Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting

03/30

Moster, Mark L

THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting

154

Europe, Canada, US, RoW

Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo

Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.

Thyroid Eye Disease

07/24

03/25

NCT05293626: Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations

Active, not recruiting

1/2

NR082 Injection, Injection needle, Syringe

Neurophth Therapeutics Inc

Leber Hereditary Optic Neuropathy (LHON)

07/25

12/29

Ellenrieder, Volker

P-MAPS, NCT04777812: Pancreatitis - Microbiome As Predictor of Severity

Completed

N/A

424

Europe

Rectal and buccal swabs

University Medical Center Goettingen, Department of Medicine II, University Hospital Rostock, Medical Department II, Division of Gastroenterology, University Hospital of Leipzig, Department of Medicine II, University Hospital, LMU Munich, Department of Medicine I, University Hospital of Halle, Department of Medicine A, University Medicine Greifswald, Department of Medicine II, University Hospital rechts der Isar, Technical University Munich, Department of Medical Bioinformatics, University Medical Center Göttingen, Department if Medical Statistics, University Medical Center Göttingen

Acute Pancreatitis

09/23

02/24

PDA-MAPS, NCT04922515: Pancreatic Ductal Adenocarcinoma - Microbiome as Predictor of Subtypes

Recruiting

N/A

200

Europe

Oral and rectal swabs for microbiome sequencing

University Medical Center Goettingen

Pancreatic Cancer

12/22

12/23

PROTOCOL, NCT05817721: PROTon Pump Inhibitors and Stent OCclusion Rate Of Lumen Apposing Metal Stents

Recruiting

N/A

639

Europe

Proton pump inhibitor, LAMS-implantation

University Medical Center Goettingen, Technical University of Munich, Ludwig-Maximilians - University of Munich, University Hospital in Halle, University of Leipzig, University Hospital Heidelberg, Landesklinikum Sankt Polten, University Hospital Schleswig-Holstein, St. Josef Hospital Bochum, Klinikum Stadt Hanau, University Hospital, Aachen, University Hospital Regensburg

Acute Pancreatitis

12/23

Kunsch, Steffen

HADRIAN, NCT05517369: Impact of Hybrid-ESD+ and LiftUp® on the en Bloc/R0 Rate in Colorectal Adenomas Between 2 and 3 cm

Withdrawn

N/A

Europe

Hybrid ESD+

Wuerzburg University Hospital, Waid City Hospital, Zurich, University Hospital Ulm, Rems-Murr-Klinikum Winnenden, Insel Gruppe AG, University Hospital Bern, Klinikum Ludwigsburg, Mathilden Hospital Herford, St. Franziskus Hospital Münster, Agaplesion Kliniken Kassel, Ovesco Endoscopy AG

Colorectal Adenoma

04/24

10/24

Korsten, Peter

BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Recruiting

440

Europe, Japan, US, RoW

Belimumab, BENLYSTA, GSK1550188, Placebo

GlaxoSmithKline

Lung Diseases, Interstitial

10/28

12/28

TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting

540

Europe, Canada, Japan, US, RoW

Litifilimab, BIIB059, Placebo

Biogen

Lupus Erythematosus, Systemic

09/25

03/26

NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis

Active, not recruiting

2/3

301

Europe, Japan, US, RoW

HZN-825 BID, Placebo, HZN-825 QD

Amgen, Horizon Therapeutics USA, Inc

Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic

09/25

ALKIVIA, NCT05523167 / 2021-001277-23: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

Recruiting

2/3

240

Europe, Canada, Japan, US, RoW

EFG PH20 SC, PBO

argenx, argenx BV

Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome

12/26

02/27

Epi_LN, NCT04648059: Epigenetics in Lupus Nephritis

Recruiting

N/A

Europe

Blood sampling

University of Göttingen, King's College London, Università degli Studi di Brescia

Systemic Lupus Erythematosus, Lupus Nephritis

12/22

06/23

RHEACT, NCT05204784: Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis

Recruiting

N/A

Europe

Rheopheresis treatment, Intravenous Infusion

Peter Korsten, DiaMed GmbH

Systemic Sclerosis, Raynaud Phenomenon, Digital Ulcer, Scleroderma

12/23

06/24

Jung, Wolfram

TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL

Recruiting

870

Europe

R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)

Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum

Mantle Cell Lymphoma

05/21

05/26

AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting

482

Europe

Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH

Multiple Myeloma

03/28

03/33

Seidler, Tim

BioVAT-HF, NCT04396899: Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure

Recruiting

1/2

Europe

EHM implantation

University Medical Center Goettingen, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), University Medical Center Freiburg, Repairon GmbH

Heart Failure

03/24

10/24

DECIPHER-HFpEF, NCT03251183: Validation of CMR Against Invasive Haemodynamics in Patients With HFpEF

Completed

N/A

185

Europe

Comprehensive Cardiovascular magnetic resonance (CMR), Blood sampling, TTE (EchoErgo), Invasive pressure-volume (PV) Loops, Left ventricular (LV) biopsy

Goethe University, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

Heart Failure With Normal Ejection Fraction

12/22

BENCHMARK, NCT04579445: Setting a Benchmark for Resource Utilization and Quality of Care in Patients Undergoing TAVI in Europe

Completed

N/A

2408

Europe, RoW

Education on tailored Quality Improvement measures, Education on Quality of Care Improvement measures

Institut für Pharmakologie und Präventive Medizin, Edwards Lifesciences

Transcatheter Aortic Valve Implantation (TAVI)

04/23

08/24

NCT02387112: Early Versus Emergency Left Ventricular Assist Device Implantation in Patients Awaiting Cardiac Transplantation

Active, not recruiting

N/A

102

Europe

Early VAD implantation

German Heart Institute, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Helmholtz Zentrum München, University Medicine Greifswald, University of Göttingen

End Stage Heart Disease

03/24

12/24

Tang, Rosa

VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies

Recruiting

143

Europe, US

Intervention/Treatment

Viridian Therapeutics, Inc.

Thyroid Eye Disease

07/25

03/26

THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting

154

Europe, Canada, US, RoW

Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo

Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.

Thyroid Eye Disease

07/24

03/25

REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting

800

Europe, US, RoW

Remibrutinib, LOU064, Teriflunomide

Novartis Pharmaceuticals, Novartis Pharma AG

Relapsing Multiple Sclerosis

04/26

10/30

NCT04607369: Implementation of the NEDS EyeCTester App

Enrolling by invitation

N/A

100

EyeCTester

Neuro-Eye Diagnostic Systems, LLC, Neuro-ophthalmology of Texas PLLC

Optic Nerve Disease, Macular Disease, Visual Pathway Disorder

01/23

MÃ¶rer, Onnen

ARISS, NCT03869385: Albumin Replacement Therapy in Septic Shock

Terminated

440

Europe

Albutein® 200 g/L or Plasbumin® 20, Human Albumin 20%

Jena University Hospital, German Research Foundation, Instituto Grifols, S.A., University Hospital Goettingen, SepNet - Critical Care Trials Group, Center for Sepsis Control and Care, Germany

Septic Shock

07/22

06/23

AGNES-19, NCT05156671: Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial

Terminated

Europe

Adrecizumab (HAM 8101), Placebo, Saline

Universitätsklinikum Hamburg-Eppendorf

COVID-19

08/23

11/23

NCT03567577 / 2017-003855-47: Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS

Recruiting

Europe

Solnatide 25 mg powder for reconstitution for solution for inhalation, AP301, 0.9% Saline Solution

Apeptico Forschung und Entwicklung GmbH

ARDS

12/24

DigiSep, NCT04571801: Optimization of Sepsis Therapy Based on Patient-specific Digital Precision Diagnostics

Recruiting

N/A

410

Europe

Standard diagnostics, Next Generation Sequencing (NGS)

University Hospital, Essen, Noscendo GmbH, Germany, Health Economics and Health Care Management, Bielefeld University, Institute of Medical Biometry and Informatics, University of Heidelberg, Coordination Centre for Clinical Trials (KKS), University of Heidelberg, Department of Infectious Diseases, University Hospital Essen, Center for Infectious Diseases and Infection Control, Jena University Hospital, Department of Anesthesiology, Heidelberg University Hospital, AOK Health Insurance, Rheinland, Hamburg, Barmer Health Insurance, Germany, Techniker Health Insurance, Germany

Sepsis, Septic Shock

02/24

08/24

NCT04249414: Post-hoc Analysis of Regional Pulmonary Perfusion and Hemodynamic Parameters Measured by Electrical Impedance Tomography

Suspended

N/A

Europe

PulmoVista 500

Drägerwerk AG & Co. KGaA, University of Göttingen, Prof. Dr. med. Imhoff

Mechanical Ventilation, Ventilation Perfusion Mismatch

06/24

12/24

Zerr, Inga

TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting

1500

Europe, RoW

Donanemab, (LY3002813), Placebo

Eli Lilly and Company

Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

04/27

KÃ¶nig, Alexander

CABONEN, NCT04524208: A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3

Active, not recruiting

Europe

Cabozantinib

Karsten Gavenis

Neuroendocrine Tumors, Neuroendocrine Carcinoma

09/24

10/24

Shafie, Rami El

XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated

166

Europe, Canada, Japan, US, RoW

Xevinapant (Debio 1143), IMRT, Placebo

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Head and Neck Cancer

08/24

PACCELIO, NCT06102057 / 2022-003408-33: - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

Recruiting

110

Europe

standard Radiotherapy, standard, Chemotherapy, Immunotherapy, Experimental Radiotherapy, Experimental

TheraOp, AstraZeneca

Stage III Non-small Cell Lung Cancer, Locally Advanced, Unresectable

06/26

06/28

SOCOFIN-1, NCT06278831: Efficacy of Structured SOcial COnsultation and Support in Reducing the FINancial Burden of Radiotherapy

Recruiting

N/A

225

Europe

Questionnaire

University Medical Center Goettingen

Financial Toxicity

05/24

10/24

ENCEPHALON, NCT03297788: Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases

Completed

N/A

Europe

SRS, WBRT

Juergen Debus, Heidelberg University

SCLC, Brain Metastases

10/23

12/23

Jordan, Jessika

PACES, NCT04045665 / 2021-005022-18: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting

3200

Europe, Canada, US

Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy

Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University Medical Center

Atrial Fibrillation, Stroke, Bleeding

08/26

Lane, Kathleen

PACES, NCT04045665 / 2021-005022-18: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting

3200

Europe, Canada, US

Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy

Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University Medical Center

Atrial Fibrillation, Stroke, Bleeding

08/26

NCT03639025: OCS™ Lung TOP Registry For Donor Lungs for Transplantation

Active, not recruiting

N/A

458

OCS Lung System

TransMedics

Lung Transplantation

11/25

11/29

PRIMARY, NCT05051033: Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds

Recruiting

N/A

450

Europe, Canada, US

Mitral valve repair, Mitral valve surgery, Transcatheter edge-to-edge repair, TEER

Annetine Gelijns, National Heart, Lung, and Blood Institute (NHLBI)

Mitral Valve Regurgitation

11/28

11/30

MOMENTIS, NCT05526560: Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve

Recruiting

N/A

500

Europe, Canada, US

MITRIS RESILIA Mitral Valve, Model 11400M

Edwards Lifesciences

Mitral Stenosis, Mitral Valve Insufficiency

01/28

12/35

Zimmermann, Wolfram-Hubertus

BioVAT-HF, NCT04396899: Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure

Recruiting

1/2

Europe

EHM implantation

University Medical Center Goettingen, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), University Medical Center Freiburg, Repairon GmbH

Heart Failure

03/24

10/24

Sala, Elisa

AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting

482

Europe

Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH

Multiple Myeloma

03/28

03/33

PHOEBUS, NCT05762211: Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications ( Trial)

Recruiting

387

Europe

Pooled allogeneic fecal microbiotherapy, MaaT033, Placebo

MaaT Pharma

Transplant Complication

10/26

02/27

RESOLVE AML001, NCT06281847: An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

Not yet recruiting

1/2

143

Europe

CCTx-001

Advesya SAS

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

07/25

08/41

NCT04230265: Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies

Recruiting

Europe

Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP), UniCAR02-T (IMP)

AvenCell Europe GmbH, PHARMALOG Institut für klinische Forschung GmbH

Acute Myeloid Leukemia (AML)

05/25

09/25

NCT05949125: Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123

Recruiting

Europe

Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123, R-TM123 is one component of the Allo-RevCAR01-T-CD123 treatment, Allo-RevCAR01-T, Allo-RevCAR01-T is one component of the Allo-RevCAR01-T-CD123 treatment

AvenCell Europe GmbH, Allucent (NL) BV

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

12/25

06/26

TAP-NSCLC, NCT06050278: Prospective Evaluation of Single Cell Mutations in a Panel of Known Oncogenes in NSCLC Surgical Specimens

Recruiting

N/A

Europe

Tapestry technology

University of Milano Bicocca

NSCLC

08/24

04/26

TAK-620-5010, NCT06615921: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

Recruiting

N/A

150

Europe, RoW

No Intervention

Takeda

Cytomegalovirus (CMV)

04/25

Koch, Jan C

NfL-ALS, NCT06201650: Neurofilament Light Chain in Amyotrophic Lateral Sclerosis

Recruiting

N/A

3000

Europe

Neurofilament light chain

Charite University, Berlin, Germany, Boris Canessa ALS Stiftung

Amyotrophic Lateral Sclerosis, Motor Neuron Disease

12/24

LIPCAL-ALS II, NCT06280079: Ultra-high-caloric, Fatty Diet in ALS

Recruiting

N/A

392

Europe

Ultra-high-caloric fatty diet, Placebo

University of Ulm

Amyotrophic Lateral Sclerosis

06/27

Puls, Miriam

Reduce-MFA, NCT05230901: Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden

Recruiting

300

Europe

Standard of Care, Spironolactone 25mg, Dihydralazine

University Medical Center Goettingen

Aortic Stenosis, Severe

06/25

03/26

Hill, Eddie

PACES, NCT04045665 / 2021-005022-18: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting

3200

Europe, Canada, US

Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy

Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University Medical Center

Atrial Fibrillation, Stroke, Bleeding

08/26

PANTHER, NCT04545502: Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches

Recruiting

N/A

2000

Europe, Canada, US

Gelsoft Plus Vascular Graft, Gelsoft Plus, Vascular Bypass Graft, Gelsoft Plus Extra Anatomical, Cardiovascular Patch, Gelseal Patch, Gelsoft Patch, Thinwall Patch, Cardiovascular Fabrics, Gelweave Vascular Graft, Gelweave, Gelweave Valsalva Vascular Graft, Gelweave Valsalva

Vascutek Ltd.

Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection, Carotid Artery Injuries, Aortic Arch, Bypass Extremity Graft, Occlusive Vascular Disease, Aortic Diseases

01/26

01/33

NCT04695171: LINX Reflux Management System or Fundoplication Clinical Study in Patients With Hiatal Hernia >3 cm

Recruiting

N/A

450

LINX Reflux Management System, Magnetic Augmentation System, Magnetic Sphincter Augmentation Device, MSAD, Magnetic Sphincter Augmentation, MSA, Fundoplication, Nissen fundoplication, Partial fundoplication, Toupet fundoplication, Watson fundoplication, Dor fundoplication

Foregut Research Foundation

Hiatal Hernia Large, Gastro Esophageal Reflux, Hiatal Hernia, Hiatal Hernia, Paraesophageal, Reflux, Gastroesophageal, Reflux Acid

01/27

01/28

Stefko, Susan

THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting

154

Europe, Canada, US, RoW

Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo

Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.

Thyroid Eye Disease

07/24

03/25

Kreuser, Anna L

SOCOFIN-1, NCT06278831: Efficacy of Structured SOcial COnsultation and Support in Reducing the FINancial Burden of Radiotherapy

Recruiting

N/A

225

Europe

Questionnaire

University Medical Center Goettingen

Financial Toxicity

05/24

10/24

Marschner, Felix

NCT06559384: Facilitators and Barriers to Dental Care in Head and Neck Cancer Patients

Enrolling by invitation

N/A

Europe

Interviews

University Medical Center Goettingen

Behavior

08/25



	Diseases Companies Products Productz Mechanisms of Action Sites